Physiomics Plc (PYC) - Total Liabilities
Based on the latest financial reports, Physiomics Plc (PYC) has total liabilities worth GBX165.00K GBX (≈ $20.08 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Physiomics Plc - Total Liabilities Trend (2001–2025)
This chart illustrates how Physiomics Plc's total liabilities have evolved over time, based on quarterly financial data. See Physiomics Plc (PYC) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Physiomics Plc Competitors by Total Liabilities
The table below lists competitors of Physiomics Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
World Chess PLC
LSE:CHSS
|
UK | GBX2.97 Million |
|
Anemoi International Ltd
LSE:AMOI
|
UK | GBX220.87K |
|
Chordate Medical Holding AB
ST:CMH
|
Sweden | Skr4.14 Million |
|
Alina Holdings PLC
LSE:ALNA
|
UK | GBX787.39K |
|
WICKET GAMING AB
F:7Q4
|
Germany | €35.31 Million |
|
Sonder Holdings Inc
NASDAQ:SOND
|
USA | $1.49 Billion |
|
Hsin Yung Chien Co Ltd
TW:2114
|
Taiwan | NT$597.24 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Physiomics Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PYC market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Physiomics Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Physiomics Plc (2001–2025)
The table below shows the annual total liabilities of Physiomics Plc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | GBX199.85K ≈ $24.32 |
+42.68% |
| 2024-06-30 | GBX140.08K ≈ $17.04 |
-1.82% |
| 2023-06-30 | GBX142.67K ≈ $17.36 |
+1.47% |
| 2022-06-30 | GBX140.61K ≈ $17.11 |
-10.76% |
| 2021-06-30 | GBX157.57K ≈ $19.17 |
+19.81% |
| 2020-06-30 | GBX131.52K ≈ $16.00 |
+52.27% |
| 2019-06-30 | GBX86.37K ≈ $10.51 |
-32.63% |
| 2018-06-30 | GBX128.21K ≈ $15.60 |
+47.50% |
| 2017-06-30 | GBX86.92K ≈ $10.58 |
-12.34% |
| 2016-06-30 | GBX99.16K ≈ $12.06 |
+86.22% |
| 2015-06-30 | GBX53.25K ≈ $6.48 |
-50.56% |
| 2014-06-30 | GBX107.71K ≈ $13.10 |
-13.59% |
| 2013-06-30 | GBX124.64K ≈ $15.17 |
+18.11% |
| 2012-06-30 | GBX105.53K ≈ $12.84 |
-5.78% |
| 2011-06-30 | GBX112.00K ≈ $13.63 |
-17.04% |
| 2010-06-30 | GBX135.00K ≈ $16.43 |
-62.50% |
| 2009-06-30 | GBX360.00K ≈ $43.80 |
-23.08% |
| 2008-06-30 | GBX468.00K ≈ $56.94 |
+129.41% |
| 2007-06-30 | GBX204.00K ≈ $24.82 |
-3.77% |
| 2006-06-30 | GBX212.00K ≈ $25.79 |
+85.96% |
| 2005-06-30 | GBX114.00K ≈ $13.87 |
-74.50% |
| 2004-06-30 | GBX447.00K ≈ $54.39 |
+114.90% |
| 2003-06-30 | GBX208.00K ≈ $25.31 |
+2211.11% |
| 2001-06-30 | GBX9.00K ≈ $1.10 |
-- |
About Physiomics Plc
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour pred… Read more